ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ascendis Pharma A/S
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Feb 11, 2026
$229.95+4.70 (+2.09%)
Close on Oct 19, 2026
Debt
Borrowings on the balance sheet, Dec 31, 2025
Total debt
€814.65M
€429.39M due within a year
Net debt
€198.60M
After €616.04M of cash
Implied interest rate
25.24%
FY2025 interest ÷ average debt
Interest coverage
-0.7×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, EUR
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Ascendis Pharma A/S's annual report. Trading prices and yields need FINRA TRACE data.